The survey was co-developed by an advisory panel of leading industry experts from AstraZeneca, Clinical Supplies Management, FibroGen, GlaxoSmithKline, OPKO Biologics, PCI Pharma Services, QuickStat Global Life Science Logistics and Sunovion Pharmaceuticals.
The survey was conducted between March and December 2016 and highlights forward looking trends in areas that influence the clinical trials supply chain – including adoption of technology, scope and pace of supply chain innovation and logistics/distribution strategy. A total of 230 healthcare industry professionals participated in the survey, representing organizations from over 20 countries and clinical supply operations across five continents.
According to Vishal Khushalani, director of global marketing and business development at Sonoco ThermoSafe, the study revealed several key insights:
- 53% of respondents from the sponsor organizations reported that they outsource more than 61% of their clinical trial supply budget.
- Close and reliable partnerships between clinical and operational teams were cited as the most important factor in successful supply forecasting: relationships with CRO 87%, distributor/packaging supplier 85% followed by the manufacturer 74%.
- 24% of the respondents currently use direct-to-patient (DTP) distribution model. One-third of those who don’t use DTP today, plan to adopt this distribution model in the next 12-18 months driven by the desire to optimise cost of recruitment, patient interactions and leverage efficiencies in data collection/visibility using technology and specialist service providers.
- 69% of respondents anticipate investment in mobile technology in the next 2 years. Lack of a user friendly interface and data security concerns topped the list of factors limiting their company’s investment in mobile technology platforms.
- Respondents found logistics between depot and clinical sites most challenging in South America, Central America and Asia. Further, the survey indicates widespread use of clinical trial supply partners, with 86% of respondents using an import broker to overcome regional challenges such as compliance with import/export regulations for shipments of clinical trial supplies.
Detailed findings will be presented at The 6th Annual Clinical Trial Supply New England conference in Boston, MA on March 8 and at subsequent Arena International Group events across North America, Europe and Asia throughout 2017. Survey results are available in the form of an infographic and a detailed report, which can be downloaded at: www.thermosafe.com/ctssurvey